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Purpose: Atherosclerotic peripheral vascular disease commonly involves the infragenicular 
arterial tree. Our study evaluated the effect ofinterleukin (IL)-ll3 on the proliferation of 
vascular smooth muscle cells (VSMCs) derived from atherosclerotic infragenicular ter- 
ies of human subjects who underwent below-kaaee amputation, as well as the role of 
IL- I~ in VSMCs' production of extracellular matrix components, ubstances that are 
important in the transformation fVSMCs from the contractile to the synthetic pheno- 
type. This transformation to the synthetic phenotype is an important step in the forma- 
tion of the atherosclerotic lesion. 
Methods: Cultures were identified as being of smooth muscle origin through staining with 
the cytoskeletal marker, 0t-smooth muscle actin. Proliferation assays were performed by 
seeding confluent cultures of passages 4 to 7 into six-well plates at 10,000 cells per well. 
After serum starvation, samples were incubated with IL-I[~ (1 ng/ml). Cell number was 
determined on a daily basis. To study extracellular matrix production, cells were propa- 
gated in tissue culture chamber slides in the absence or presence of growth media 
containing IL-113. After fixation with 100% methanol, each sample was stained with a 
primary antibody specific for an extracellular matrix component. After staining with the 
fluorescein-tagged s condary antibody, each sample was examined using immunofluores- 
cent microscopic examination. 
Results: The results of our proliferation assays howed that IL-I[~ caused a significant 
increase in the proliferation of VSMCs at 24, 48, 72, and 96 hours (p --- 0.003 when 
comparing IL-113-treated samples with control specimens at each time period using 
unpaired t test). The number of IL-l[~-treated cells at 96 hours was double the number 
present in the control samples (16,033 -+ 238 vs 8102 4- 824). When compared with 
control samples, IL-1I~ was found to affect the production of extracellular matrix 
proteins by infragenicular VSMCs. IL- I~ caused an increase in the production of 
fibronectin, a decrease in the production of laminin, and no change in the production of 
collagen type IV. 
Conclusions: These results suggest that interleukin- 1~ acts as a potent stimulant of the 
proliferation of human infragenicular VSMCs. IL-113 also acts to augment the produc- 
tion of fibronectin by these cells. Fibronectin has been implicated in the phenotypic 
transformation fVSMCs from the contractile to the synthetic state. Therefore, IL-1I$ 
may serve as an important regulatory factor in the development of atherosderosis by 
stimulating the proliferation of VSMCs and their transformation to the synthetic state, 
two important s eps in the formation of the atherosclerotic lesion. (J Vasc Surg 1997; 
26:1002-8.) 
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A critical feature in the pathogenesis of athero- 
sclerosis is the phenotypic transformation fvascular 
smooth muscle cells (VSMCs) from the contractile 
to the synthetic state. Changes in VSMC phenotype 
have been associated with components of the sur- 
rounding extracellular matrix) ,2 The resultant syn- 
thetic form of VSMC is found within the intimal 
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layer of the arterial wall. The VSMC proliferates to 
produce the core of the atherosclerotic plaque. 3,4 In 
addition to its actions as an inflammatory mediator, 
interleukin (IL)-I~ is believed to be an important 
mitogenic substance that induces cellular prolifera- 
tion. Although atherosclerosis is a generalized is- 
ease of the peripheral vascular tree, in patients who 
have diabetes it occurs in a specific pattern of distri- 
bution, typically involving the anterior tibial, poste- 
rior tibial, and peroneal arteries (collectively referred 
to as infragenicular teries). Progression of this ath- 
erosclerotic process threatens the viability of the 
lower extremity and necessitates the performance of 
distal arterial bypass procedures for limb salvage, s We 
established and characterized VSMCs that were de- 
rived from the infragenicular teries of human sub- 
jects. 6In this study we examined the effect of IL-113 
on the proliferation of human infragenicular VSMCs, 
as well as its effect on the production of extracellular 
matrix proteins, fibronectin, collagen type IV, and 
laminin in culture. 
MATERIALS AND METHODS 
VSMC origin. The VSMCs that were used in 
these experiments were derived from the atheroscle- 
rotic infragenicular arteries of five human subjects 
with diabetes; the arteries were obtained uring be- 
low-knee amputation procedures. These cells were 
identified as being of smooth muscle origin through 
immunohistochemical st ining and electron micros- 
copy. 6 Secondary cell cultures of passages 4 to 7 were 
used in all experimental trials. 
IL-1lg dose-response tudies. The role of vari- 
ous IL-113 concentrations on the proliferation of 
VSMCs was determined through a series of dose- 
response xperiments. After an initial 48,hour incu- 
bation in media containing 10% fetal bovine serum, 
the previously seeded six-well plates were deprived of 
serum for the remainder of the test period. Using 
four different concentrations ranging from 0.5 
ng/ml  to 10 ng/ml,  IL-I~3 was added to each test 
well on a daily basis. After 48 hours of exposure to 
the IL-113 enriched media, each sample was counted 
using a standard hemocytometer. 
Proliferation assays. To study the effect of 
IL-lJ3 on the proliferation rate of VSMCs, cells from 
the subconfluent cultures were detached using 0.25% 
trypsin ethylenediamine t traacetic acid and were 
seeded into six-well plates at 10,000 cells per well. 
C199 growth media supplemented with 10% fetal 
bovine serum was added for a final volume of 2.5 ml 
per well. All plates were incubated for a period of 48 
hours to allow for cellular attachment. Subsequently, 
the media was removed and the cells were washed 
with copious amounts of phosphate-buffered saline 
solution. The plated cells then underwent a 24-hour 
period of serum starvation. After serum deprivation, 
IL- 1 (3 (1 ng/ml)  was administered daily to each well 
in the test group. Matched control samples were 
maintained in serum-free media alone. At the con- 
clusion of the 96 hour period, exposure to IL-113 was 
terminated and all samples were counted using he- 
mocytometric techniques. The experiments were 
replicated a minimum of three times. 
Studies of  extracellular matrix production. 
The techniques of immunohistochemical analysis 
were used to study the effect of IL-113 on extracellu- 
lar matrix protein production by the human infra- 
genicular VSMCs. The test samples for this series of 
experiments underwent treatment that was identical 
to the protocol described for the proliferation assays. 
At the conclusion of the 96-hour treatment period, 
all cells were incubated in 100% methanol at -20 ° C 
for 10 minutes to allow for fixation. After fixation, 
staining with one of three primary antibodies was 
performed. The primary antibodies used in this series 
of experiments were (1) 1:150 monoclonal anticellu- 
lar fibronectin; (2) 1:150 monoclonal anticellular 
laminin; and (3) 1:150 anticellular collagen type IV 
(all primary antibodies obtained from Sigma, St. 
Louis). After a 45-minute incubation with the pri- 
mary antibody, a fluorescein-tagged secondary anti- 
body (1:100 dilution) was applied to each test sam- 
ple. After a second 45-minute incubation period, all 
samples were thoroughly washed and mounted with 
SlowFade antifade reagent. Coverslips were affixed, 
and each specimen was examined under an epifluo- 
rescence microscope. To detect any autofluores- 
cence, slides without any immunohistochemical 
stains were prepared and examined. 
Statistical analysis. One-way analysis of vari- 
ance was used to detect significance in analyzing 
multiple groups in the dose-response proliferation 
assays. A posterior test (Tukey) was used to analyze 
further the difference between each two groups. An 
unpaired t test was used to compare IL-1 ~3-treated 
samples with control samples at each time period. A p 
value less than 0.05 was considered to be significant. 
RESULTS 
In these VSMCs, IL-113 increased cellular prolif- 
eration in a dose-dependent manner. All concentra- 
tions of IL-113 used in our dose-response studies 
produced asignificant rise in cell number when com- 
pared with the control group. We observed an in- 
crease in cell number, which ranged from 87% in the 
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Fig. 1. Effect of IL-I[~ on proliferation of human infra- 
genicular VSMCs. *p < 0.001 using unpaired t test to 
compare IL-l[3 treated cells with control cells at each time 
period. 
test group treated with 0.5 ng /ml  of IL-113 (5860 + 
390, n = 8; vs 3348 + 223, n = 7; p < 0.05) to 
243% in the test group treated with 10 ng /ml  of 
IL-113 (10,714 + 717, n = 7; vs 3348 _+ 223, n = 7; 
p < 0.05). Additional analysis of the experimental 
findings demonstrated that an IL-l[3 concentration 
of 1 ng /ml  resulted in a statistically significant in- 
crease in cell number when compared with samples 
treated with an IL-113 dose of 0.5 ng /ml  (8334 + 
637, n = 9; vs 5860 + 390, n = 8; p < 0.05). In 
contrast, no significant difference in cell number was 
observed between the groups treated with I ng /ml  
and 5 ng /ml  of IL-113 (8334 _+ 637, n = 9; vs 
8789 +-- 777, n = 8; p = NS) or between the groups 
treated with 1 ng /ml  and 10 ng /ml  (8334 + 637, 
n = 9; vs 10,714 _+ 717, n = 7; p = NS). Therefore, 
a 1 ng /ml  dose of IL-113 was used for the prolifera- 
tion assays. The results of our proliferation assays 
using an IL-113 dose of 1 ng /ml  are depicted in Fig. 
1. A statistically significant increase in cell number 
was achieved in the test groups at each time period 
when compared with the control samples. In addi- 
tion, the administration of IL-1 [3 produced a signifi- 
cant increase in cell number among the treated sam- 
ples within 96 hours in comparison with the control 
samples (16,033 +_ 283, n = 8; vs 8102 +_ 823, n = 
7; p < 0.001). Of  note, because of cell death there 
was a considerable drop in cell number at day I in the 
control group. IL-l[3-treated cells did not experi- 
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Fig. 2. Composlte immunofluorescence photomicro- 
graph shows distribution of fibronectin in subconfluent 
monolayer of human infragenicular VSMCs. IL-I[3- 
treated cells (A) produce more extensive and deeply 
stained fibronectin fibers when compared with control cells 
(B). Arrows point to fibers located along contour of cells. 
ence such cell loss. At day 2 the control cells contin- 
ued to decrease in number, whereas ceils treated by 
IL-1 [3 increased in number significantly. 
Even at days 3 and 4 control cells remained well 
below baseline number, whereas cells treated with 
IL-113 followed an upward trend, which indicated 
that IL-113 stimulated the proliferation of these cells. 
Our immunohistochemical studies of IL-113- 
treated cells revealed an increase in fibronectin pro- 
duction. As denoted in Fig. 2, the fibronectin pro- 
duced by the IL-l[3-treated cells is more organized 
and deeply stained than its untreated counterpart. In 
contrast, IL-113-treated cells produced less of the 
extracellular matrix protein collagen type IV when 
compared with the control samples (Fig. 3). Finally, 
there appears to be an equal distribution of laminin 
among both treated and untreated ceils. This finding 
indicates that IL-I[~ has no effect on the formation 
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Fig. 3. Composite immunofluorescence photomicro- 
graph shows the distribution of collagen IV in subconflu- 
ent monolayer of human infragenicular VSMCs. Note de- 
crease in collagen IV production i IL- 1 p-treated cells (A) 
when compared with control cells (B). 
Fig. 4. Composite immunofluorescence photomicro- 
graph shows the distribution of laminin in subconfluent 
monolayer of human infragenicular VSMCs. No obvious 
difference can be seen in the density of laminin fibers 
between IL-113-treated cells (A) and control cells (B). 
and deposition oflaminin by the VSMCs, as demon- 
strated in Fig. 4. 
DISCUSSION 
Occlusive vascular disease of the infragenicular 
vasculature is a serious problem that may lead to limb 
loss and major disability. Progression of such lesions 
often necessitates distal arterial reconstruction to re- 
store blood flow and salvage the threatened limb. s 
Infragenicular vascular disease is the predominant 
distribution of peripheral atherosclerosis, n certain 
situations, most notably in patients with diabetes. A
central element in the formation of the atheroscle- 
rotic plaque is the VSMC. After endothelial injury, 
VSMCs migrate from the medial to the intimal ayer 
of the arterial wall. Within the intima the VSMCs 
undergo phenotypic modulation from the contractile 
to the synthetic state. This phenotypic hange is 
characterized by an accumulation of  organclles nec- 
essary for cell division. Subsequently, the intimal 
VSMCs undergo proliferation to form the core of  the 
advanced atherosclerotic lesion. 7-9 Extracellular ma- 
trix proteins such as fibronectin, collagen type IV, 
and laminin play an important role in the transforma- 
tion of the VSMCs from the contractile to the syn- 
thetic state, which is an important step in the forma- 
tion of the atherosclerotic lesion) Fibronectin, in 
particular, is an important factor in inducing the 
transformation ofVSMCs. It appears that a 105-kD 
cell-binding fragment of fibronectin modulates the 
transformation fVSMCs to the synthetic form. The 
transformation of VSMCs to a synthetic phenotype 
was complete in response to the 105-kD fragment 
and resulted in synthetic ells similar to those that 
resulted from the effect of the complete molecule of 
fibronectin. In contrast, the 70-kD collagen binding 
fragment and the 31-kD heparin-binding fragment 
of fibronectin resulted in the attachment of the cell 
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but did not induce its transformation into the syn- 
thctic state. In contrast to fibroncctin, collagen type 
IV and laminin did not encourage, and even delayed, 
the transformation of VSMCs into the synthetic 
state. 2,1° Contractile VSMCs are able to produce 
these extracellular matrix proteins2; therefore, these 
cells can cause their own transformation to the syn- 
thetic state. 
Several circulating cytokines, including IL-lJ~, 
have been implicated as control mechanisms in the 
pathogenesis of atherosclerosis. IL-I[3 is a multipo- 
tent inflammatory mediator that is encoded on chro- 
mosome 2. Although it was initially described as a 
product of mononuclear leukocytes, IL-I~ is pro- 
duced by a variety of cells, including VSMCs. 11,12 
After its release, IL-113 binds to a cell surface recep- 
tor, resulting in a myriad of biologic effects. IL-lJ3 
has been shown to induce both IL-1 and growth 
factor production by the VSMCs, initiating an auto- 
crine feedback loop that accelerates VSMC growth 
and proliferation.ll Importantly, IL- lJ3 has been im- 
plicated as a regulator in the production of extracel- 
lular matrix constituents in animal cells. Injection of 
recombinant IL-1 in the abdominal cavity has been 
shown to increase plasma and liver fibronectin in 
rats. ~3 This effect has been found to be mediated by 
IL-6 in rat hepatocytes) 4 In studying human aortic 
smooth muscle cells, IL-I[~ was found to cause a 
decrease in the production of messenger RNA for 
type 1 procollagen i  a dose-dependent manner by 
cells derived from normal and aneurysmal ortas) 5
Because the conversion to the synthetic pheno- 
type is necessary for VSMC intimal proliferation and 
has been linked to extracellular matrix composition, 
our experiments studied the effect of IL-lJ3 on the 
production of fibronectin, collagen type IV, and 
laminin by human VSMCs derived from tibiopero- 
neal origin. Our results revealed an increase in the 
deposition of fibronectin by the VSMCs after treat- 
ment with IL-1 J~. Fibronectin manufactured bythe 
VSMCs was organized into dense fibrils and incorpo- 
rated into a pericellular network. Conversely, IL-1{3 
treatment produced a decline in the formation of 
collagen type IV when compared with the control 
samples. Laminin deposition was not affected by the 
administration f IL-lJ3. Our findings support he 
hypothesis that IL-lf3 indirectly impacts the pheno- 
type of VSMCs through its augmentation of fi- 
bronectin deposition and the decrease in type IV 
collagen synthesis. 
Our proliferation studies revealed a direct effect 
oflL-l[3 on the proliferative capacity of human infra- 
genicular VSMCs. Treatment of these VSMCs with 
IL-I~ at a concentration of 1 ng/ml produced a
statistically significant increase in cell number for 
each 24-hour period when compared with samples 
incubated in serum-free media. Results from dose- 
response experiments indicate that the effect of 
IL-1{3 is concentration-dependent, producing statis- 
tically significant increases in cell number anging 
from 87% for a dose of 0.5 ng/ml to 243% for a dose 
of 10 ng/ml. 
CONCLUSION 
These results suggest two mechanisms by which 
IL- 1 J~ may hasten the development of atherosclerosis 
in the human infragenicular terial tree. By increas- 
ing fibronectin deposition and decreasing collagen 
type IV production by VSMCs derived from human 
tibioperoneal origin, IL-lJ~ promotes phenotypic 
transformation f infragenicular VSMCs from the 
contractile to the synthetic state. In addition, IL-1 f3 
acts as a mitogenic agent, producing significant in- 
crease in the proliferation rate of the VSMCs. These 
findings uggest that IL- 1 J3 may play a central role in 
the formation oftibioperoneal atherosclerotic lesions 
through its effect on cellular phenotype transforma- 
tion as well as its direct impact on the proliferative 
capacity of the VSMCs. The dual nature of the effect 
of IL-1{3 on VSMCs makes this cytokine an impor- 
tant target in efforts aimed at the inhibition of the 
formation of tibioperoneal peripheral vascular dis- 
ease, a characteristic distribution i the diabetic pop- 
ulation. 
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DISCUSSION 
Dr. Thomas F. Panetta (Brooldyn, N.Y.). I would 
like to congratulate he authors on a very nicely performed 
experiment, and Dr. Forsyth for an excellent presentation. 
This experiment using smooth muscle cell explants 
from tibioperoneal segments, when stimulated with exog- 
enous IL-I[3, a proinflammatory c tokine, resulted in in- 
creased smooth muscle cell proliferation, increased fi- 
bronectin, decreased collagen type IV, and no change in 
laminin. I think these are important findings that have 
specific implications to atherosclerosis and possibly dia- 
betic vascular disease. The authors' conclusions were that 
IL- 1 [3 mediates smooth muscle cell proliferation and that it 
mediates the transformation f smooth muscle cells from a 
contractile to a synthetic state based on the findings of 
extracellular matrix components. 
Although the authors have convincingly shown their 
first conclusion that IL-I[3 mediates mooth muscle cell 
proliferation, from these data, including a dose-response 
curve, I am not totally convinced about he second conclu- 
sion. I would like to ask Dr. Forsyth to comment on the 
design of the experiments; specifically, the smooth muscle 
cells were taken from end-stage vascular patients. What 
implication does this have on your results and conclusions? 
I have a number of other questions. 
The first relates to the amputation specimens. How 
many specimens did you use? What were the ages of these 
patients? How many had diabetes? Did you exclude pa- 
tients without diabetes? Were any of these patients renal 
failure patients? Were these tibioperoneal segments oc- 
cluded? Were they patent? And how much disease was 
there in these segments? 
Along these lines, did you consider differences in the 
smooth muscle cells from patients with and without diabe- 
tes? For example, did you perform the experiments with 
subsets of cells from patients with and without diabetes, or 
were these all patients diabetes? The issue here relates to 
the genotype of the cell that's tudied and the effect on the 
phenotypic hanges that occurred to speed differentiation 
into the phenotypic hange that increased extracellular 
matrix production. 
The issue here is whether these were diabetic geno- 
types or is this just a generic effect where IL-I[3 increases 
smooth muscle cell proliferation? This may have important 
impact on atherosclerosis in general, but I would like you 
to convince me that this is specifically related to patients 
with diabetes and smooth muscle cells from patients with 
diabetes. 
What other evidence do you have of these phenotypic 
changes to the synthetic state? You provided indirect evi- 
dence from the extracellular matrix production of fibronec- 
tin, and this has implications with regard to this change to 
the synthetic state, but have you looked, for example, at 
increase in rough endoplasmic reticulum production in 
these cells, providing specific evidence that these cells have 
been transformed into the synthetic state? 
Could you comment on the significance and the differ- 
ences in the results of the extracellular matrix, specifically 
fibronectin, type IV collagen, and did you consider, for 
example, type II I collagen or type I collagen, which have 
been shown to be important in extracellular matrix pro- 
duction, for example, in intimal hyperplasia? 
Could you comment on the possible mechanism? Did 
you look at transforming growth factor-J31, and could this 
have any effect on this phenotypic modulation and dedif- 
ferentiation? 
Finally, your smooth muscle cells came from tibiopero- 
neal segments. What evidence do you have that this is 
specific for that location? Have you looked at smooth 
muscle cell explants, for example, from aortic scgments, 
and have you considered measuring IL-113 in the tissue 
itself?. The other thing is that you had a conclusion in your 
presentation, which I didn't see in the manuscript, relating 
to a local effect of the IL-1 [3. Did you measure serum levels 
oflL-l[3 or local tissue levels ofIL-1 [3 to again show that it 
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has a specific effect and that this is site-specific, again 
relating to the issue of whether this is just related to 
atherosclerosis in general or specific to diabetic vascular 
disease? 
Dr. Elizabeth A. Forsyth. To address the first point, 
the arterial segments were all taken from patients with 
diabetes who ranged in age from approximately 58 to 67 
years. All of the specimens were obtained from severely 
stenosed or completely occluded tibioperoneal segments 
from patients who were not considered candidates for 
bypass procedures. None of the patients were on dialysis. 
Therefore, these results were obtained in diabetic patients 
with end-stage peripheral vascular disease, and the conclu- 
sions that we have reached apply to that group of patients. 
As far as the effect of IL-1 [3 is concerned, it is well known 
that this cytokine causes proliferation of smooth muscle 
cells in general; our study shows the effect of this growth 
factor in a specific vascular bed that is usually affected by 
the atherosclerotic process in patients who have diabetes. 
Concerning the synthetic state of these cells, we have 
already studied that situation, and it was the subject of an 
earlier study that was published in the Journal of Vascular 
Surgery. 6 Multiple reports have shown that fibronectin 
causes the conversion of smooth muscle cells from the 
contractile to the synthetic pheuotype. As far as the effect 
of transforming rowth factor-[3 on the proliferation of 
these smooth muscle cells, we have shown in an earlier 
study that this growth factor causes inhibition of the pro- 
liferative ffect of insulin on these cells. Again, these data 
were published in the Journal of Vascular Surgery (Forsyth 
et al.; 1997;25:432-6). 
Dr. Patrick DeI' ippo (Brooklyn, N.Y.). We would 
like to congratulate Dr. Forsyth on her presentation. We 
too are interested in the role of IL-1 in the pathogenesis of
atherosclerosis and last year presented at the SVS the role 
of the IL-1 receptor antagonist and its reduction of intimal 
hyperplasia in a rat carotid artery injury model. In that 
model we found about a 30% reduction as a result of 
48-hour injection of IL-1 receptor antagonist. However, 
in this animal model, which, of course, is for a period of 2 
weeks, that the mean cross-sectional diameter in the intima 
is largely related to increase in cell number and migration 
of smooth muscle cells into the intima rather than a pro- 
duction of extracellular matrix. The kinetics of this animal 
model have been studied extensively by Dr. Clowes, who 
found that the matrix expands at approximately the 6- 
month range, and I was just wondering what your feelings 
on this issue are and whether you'd like to comment on it? 
Dr. Forsyth. On the issue of IL-1 and how it affects 
the expansion of matrix? 
Dr. DePippo. Smooth muscle cell migration and rep- 
lication in the intima. 
Dr. Forsyth. Well, in this setup, we have shown that 
IL-1 causes ignificant proliferation of these smooth mus- 
cle cells. As far as whether IL-1 acts as a chemotactic agent 
in this cell population, we have not performed studies to 
evaluate that, and so it would be premature for me to 
comment. 
Dr. John J. Ricotta (Buffalo, N.Y.). That was a very 
nice presentation. I just wanted to ask whether you have 
performed any studies on whole vessel segments where you 
looked at the amount of your extracellular matrix proteins 
and the relative amounts of those proteins, particularly in 
your tibial vessels. It might give some in vivo correlation to 
your in vitro results. 
Dr. Forsyth. This study focused primarily on cell cul- 
ture. 
Dr. Anton N. Sidawy. Let me add to that comment. 
In our original article in the Journal of Vascular Surgery 
reporting on the characterization f these cells, 6we have 
shown that, after multiple passages, these cells still main- 
tained a very thickened basal amina that is basically made 
of extracellular proteins. When we went back and per- 
formed electron microscopic studies on tibial artery blocks, 
we found the thickened basal lamina that we found in 
culture. 
Dr. Ricotta. But you haven't taken segments of whole 
artery and tried to analyze whether those tibial arteries have 
a different extracellular matrix composition percentagewise 
than the arteries? 
Dr. Sidawy. No, we have not done that. 
